nach oben

Erschienen in:

01.05.2015 | Case Report

A case of cryopyrin-associated periodic syndrome with kidney transplant failure

verfasst von: Rie Imaizumi, Yasuo Ishii, Katsuyuki Miki, Shinji Kudo, Toru Murakami, Ichiro Koyama, Ichiro Nakajima, Shohei Fuchinoue, Yasushi Kawaguchi, Atsuo Taniguchi, Satoshi Teraoka

Erschienen in: CEN Case Reports | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

The cryopyrin-associated periodic syndrome (CAPS) is an autosomal dominant autoinflammatory disease characterized by fever, skin rash, and joint involvement with acute inflammatory response. The genetic defect involves the NLRP3 gene that encodes cryopyrin and leads to an abnormal production of interleukin-1 (IL-1). Therefore, anti-IL-1 treatment represents an effective therapy. One of the most severe manifestations of the disease is secondary amyloidosis that causes renal failure. We present a patient with CAPS who underwent renal transplantation for renal insufficiency caused by amyloidosis. The function of the transplanted kidney deteriorated because of the late administration of IL-1 receptor antagonist, anakinra. This case may indicate the importance of early initiation of anti-IL-1 treatment in CAPS patients who have undergone kidney transplantation.

Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le Bozec J, Delpech M, Amselem S, Touitou I, French CAPS study group. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from 8 years of genetic analysis in France. Ann Rheum Dis. 2011;70:495–9.CrossRefPubMed

Tilson H, Primatesta P, Kim D, Rauer B, Hawkins PN, Hoffman HM, Kuemmerle-Deschner J, van der Poll T, Walker UA. Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry. Orphanet J Rare Dis. 2013;8:139.CrossRefPubMedCentralPubMed

Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep. 2011;13:123–31.CrossRefPubMedCentralPubMed

Kim PW, Aksentijevich I, Colburn NT, Kastner DL. Hereditary recurrent fevers. In: Hockberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Elsevier; 2011. p. 1637–57.CrossRef

Aksentijevich I, Putnam CC, Remmers EF, Mueller JL, Le J, Kolodner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R, Hoffman HM, Kastner DL. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007;56:1273–85.CrossRefPubMedCentralPubMed

Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol. 2005;17:586–99.CrossRefPubMed

Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, Roberts PF, Woo P, Grattan CE, Hawkins PN. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006;142:1591–7.CrossRefPubMed

Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis. 2007;49:477–81.CrossRefPubMed

Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62:258–67.CrossRefPubMed

10.

Aït-Abdesselam T, Lequerré T, Legallicier B, François A, Le Loët X, Vittecoq O. Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. Jt Bone Spine. 2010;77:616–7.CrossRef

11.

Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, Lohse P, Koitchev A, Deuter C, Foell D, Benseler SM. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle–Wells syndrome. Arthritis Rheum. 2011;63:840–9.CrossRefPubMed

12.

Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, Russell TL, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum. 2013;65:1116–21.CrossRefPubMed

13.

Enríquez R, Sirvent AE, Padilla S, Noguera-Pons R, Andrada E, Ardoy F, Millán I, Amorós F. Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome. Ren Fail. 2013;35:738–41.CrossRefPubMed

14.

Scarpioni R, Rigante D, Cantarini L, Ricardi M, Albertazzi V, Melfa L, Lazzaro A. Renal involvement in secondary amyloidosis of Muckle–Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. Clin Rheumatol. (2014) [Epub ahead of print].

15.

Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O’Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, Cole JL, Paul SM, Hawkins PN, Pham TH, Snyder C, Wesley RA, Hoffmann SC, Holland SM, Butman JA, Kastner DL. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med. 2006;355:581–92.CrossRefPubMedCentralPubMed

16.

Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, Finetti M, Battagliese A, Martini G, Bibalo C, Martini A, Gattorno M. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013;15:R33.CrossRefPubMedCentralPubMed

17.

Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, Koetter I, Lohse P, Ummenhofer K, Reess F, Hansmann S, Koitschev A, Deuter C, Bialkowski A, Foell D, Benseler SM. Treatment of Muckle–Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther. 2013;15:R64.CrossRefPubMedCentralPubMed

18.

Pinney JH, Lachmann HJ, Sattianayagam PT, Gibbs SD, Wechalekar AD, Venner CP, Whelan CJ, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD. Renal transplantation in systemic amyloidosis—importance of amyloid fibril type and precursor protein abundance. Am J Transpl. 2013;13:433–41.CrossRef

19.

Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, Lachmann HJ, Lang U, Kovarik J. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transpl. 2009;24:676–8.CrossRef

20.

Tanaka F, Migita K, Honda S, Fukuda T, Mine M, Nakamura T, Yamasaki S, Ida H, Kawakami A, Origuchi T, Eguchi K. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol. 2003;21:343–6.PubMed

21.

Caroli F, Pontillo A, D’Osualdo A, Travan L, Ceccherini I, Crovella S, Alessio M, Stabile A, Gattorno M, Tommasini A, Martini A, Lepore L. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology. 2007;46:473–8.CrossRefPubMed

22.

Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN, Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. New Engl J Med. 2009;360:2416–25.CrossRefPubMed

23.

Yokota S, Nishikomori R, Takada H, Kikuchi M, Nozawa T, Kanetaka T, Kizawa T, Miyamae T, Mori M, Heike T, Hara T, Imagawa T. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan. Mod Rheumatol. 2013;23:425–9.CrossRefPubMed

24.

Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, Hoyer J, Gattorno M, Gul A, Smith J, Leslie KS, Jiménez S, Morell-Dubois S, Davis N, Patel N, Widmer A, Preiss R, Lachmann HJ. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70:2095–102.CrossRefPubMed

Titel: A case of cryopyrin-associated periodic syndrome with kidney transplant failure
verfasst von: Rie Imaizumi
Yasuo Ishii
Katsuyuki Miki
Shinji Kudo
Toru Murakami
Ichiro Koyama
Ichiro Nakajima
Shohei Fuchinoue
Yasushi Kawaguchi
Atsuo Taniguchi
Satoshi Teraoka
Publikationsdatum: 01.05.2015
Verlag: Springer Japan
Erschienen in: CEN Case Reports / Ausgabe 1/2015
Elektronische ISSN: 2192-4449
DOI: https://doi.org/10.1007/s13730-014-0129-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

A case of acute kidney injury and disseminated intravascular coagulation associated with influenza B viral infection

Successful management of bilateral emphysematous pyelonephritis with abscess formation in a chronic hemodialysis patient: a case report

Henoch–Schönlein purpura complicated with severe gastrointestinal bleeding

Atopic dermatitis, cyclosporine, and nephrotoxicity

Alendronate associated focal segmental glomerulosclerosis: a case report and review of the literature

Post-infectious acute glomerulonephritis with vasculitis and pulmonary hemorrhage